share_log

HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $2 Price Target

Benzinga Real-time News ·  Feb 3, 2023 01:18

HC Wainwright & Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment